

# Rebecca Anne Miksad

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8710156/rebecca-anne-miksad-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39  
papers

3,173  
citations

21  
h-index

44  
g-index

44  
ext. papers

3,937  
ext. citations

4.8  
avg, IF

4.49  
L-index

#	Paper	IF	Citations
39	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	1
38	Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	0
37	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
36	Real-world association of HER2/ concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 4101-4114	3.6	2
35	Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 389-394.e3	4.9	7
34	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e207205	10.4	10
33	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , <b>2020</b> , 49, 193-200	2.6	10
32	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6158-6167	12.9	21
31	Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. <i>Advances in Therapy</i> , <b>2019</b> , 36, 2122-2136	4.1	54
30	Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 87-90	6.1	10
29	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. <i>JCO Clinical Cancer Informatics</i> , <b>2019</b> , 3, 1-13	5.2	36
28	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. <i>Cancer</i> , <b>2019</b> , 125, 4019-4032	6.4	53
27	Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. <i>Oncologist</i> , <b>2019</b> , 24, 648-656	5.7	44
26	Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 550-8	2.2	1097
25	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 840-9	13.4	96
24	Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. <i>Hpb</i> , <b>2014</b> , 16, 1009-15	3.8	14
23	A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. <i>Surgery</i> , <b>2013</b> , 154, 545-55	3.6	22

22	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1608-16	4.5	32
21	Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2963-8	2.2	216
20	Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, e615-22	4	169
19	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. <i>Liver Transplantation</i> , <b>2011</b> , 17 Suppl 2, S147-58	4.5	13
18	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. <i>Cancer</i> , <b>2011</b> , 117, 5094-102	6.4	154
17	Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. <i>Oncologist</i> , <b>2011</b> , 16, 121-32	5.7	99
16	Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 918-27	12.9	26
15	Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. <i>Oncologist</i> , <b>2010</b> , 15, 1179-91	5.7	58
14	Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 78, 735-42	4	179
13	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3027-35	2.2	417
12	Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2245-52	2.2	16
11	Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. <i>Journal of Gastrointestinal Cancer</i> , <b>2009</b> , 40, 119-22	1.6	1
10	Methods for measuring temporary health States for cost-utility analyses. <i>Pharmacoeconomics</i> , <b>2009</b> , 27, 713-23	4.4	37
9	Measuring the quality-of-life effects of diagnostic and screening tests. <i>Journal of the American College of Radiology</i> , <b>2009</b> , 6, 567-75	3.5	9
8	Progression-free survival as a surrogate endpoint in advanced breast cancer. <i>International Journal of Technology Assessment in Health Care</i> , <b>2008</b> , 24, 371-83	1.8	67
7	Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. <i>International Journal of Technology Assessment in Health Care</i> , <b>2008</b> , 24, 184-92	1.8	17
6	Detection of prostate cancer following gender reassignment. <i>BJU International</i> , <b>2008</b> , 101, 259; author reply 259-60	5.6	15
5	Treatment of cancer pain with noninvasive brain stimulation. <i>Journal of Pain and Symptom Management</i> , <b>2007</b> , 34, 342-5	4.8	21

4	Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4506-7; author reply 4508	2.2	62
3	Prostate cancer in a transgender woman 41 years after initiation of feminization. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2316-7	27.4	36
2	From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. <i>Journal of Urban Health</i> , <b>2005</b> , 82, 498-509	5.8	32
1	Hepatic hydrothorax associated with vitamin a toxicity. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 34, 275-9	3	14